Raetasha Dabney is an Oncology physician. OpenAlex indexes 17 publications with 482 citations (h-index 9).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
431 E State Highway 114 Ste 470
Southlake, TX 760924415
Telephone
214-379-2700Provider last certified this registry record 19 Apr 2020.
Industry payments
43 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Novartis Pharmaceuticals CorporationProgram year202514 payments
- AstraZeneca Pharmaceuticals LPProgram year20254 payments
- Janssen Biotech, Inc.Program year20254 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
76.7%PD-1 inhibitor71.7%Pembrolizumab100%Part B, office-administered≥13 patientsNucleoside Metabolic Inhibitor2.3%Fluorouracil100%Part B, office-administered≥11 patients+ 6 more classes in this area
Sensory organs
10.9%Corticosteroid10.9%Dexamethasone sodium phosphate99%Dexamethasone2%Part D + Part B<11 patientsMetabolism & gastrointestinal
9.2%Serotonin-3 Receptor Antagonist9.1%Granisetron hydrochloride61%Palonosetron hcl38%Ondansetron Hcl1%Part D + Part B≥16 patientsPotassium supplement0.1%Potassium Chloride100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Treatment of Multiple Myeloma: ASCO–Ontario Health (Cancer Care Ontario) Living Guideline
Journal of Clinical Oncology
2026 - Systemic Therapy for Small Cell Lung Cancer: ASCO Guideline Rapid Recommendation Update
Journal of Clinical Oncology
2024 - Systemic Therapy for Small-Cell Lung Cancer: ASCO-Ontario Health (Cancer Care Ontario) Guideline
Journal of Clinical Oncology
2023 - Immunotherapy and Biomarker Testing in Recurrent and Metastatic Head and Neck Cancers: ASCO Guideline
Journal of Clinical Oncology
2022
Similar KOLs
Other experts from the same institution or the same specialty.
Freddie Bray
Centre National de la Recherche Scientifique
Jacques Ferlay
Centre international de recherche sur le cancer
Hermann Brenner
German Cancer Research Center
Isabelle Soerjomataram
Centre international de recherche sur le cancer
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”